Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924754 · ClinicalTrials.gov registry record
Gardasil Immunogenicity With Needle-Free Injection
A clinical trial of HPV Seroconversion, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 150
- Enrollment target
- 2
- Study locations
NCT01924754 is a study of HPV Seroconversion that has completed, run by University of California, San Francisco. The registered enrollment target is 150 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT01924754, a study of HPV Seroconversion, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
Using biospecimens collected in a trial by the Thai Red Cross AIDS Research Center that studied two new human papillomavirus (HPV) vaccine delivery regimens, the investigators at UCSF will be testing the serum for antibodies to measure the strength of their response to the vaccine.
Conditions Studied
Study Locations (2)
California
- University of California, San Francisco - San Francisco
Other
- Thai Red Cross AIDS Research Centre - Bangkok
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2014-01-01 |
| Est. Completion | 2016-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01924754
The ClinicalTrials.gov registry entry for NCT01924754 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HPV Seroconversion appearing as the primary indexed condition, and to 0 interventions.
NCT01924754 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Other.
Frequently Asked Questions
What is clinical trial NCT01924754 about?
NCT01924754 is a clinical study titled "Gardasil Immunogenicity With Needle-Free Injection". Using biospecimens collected in a trial by the Thai Red Cross AIDS Research Center that studied two new human papillomavirus (HPV) vaccine delivery regimens, the investigators at UCSF will be testing the serum for antibodies to measure the strength of their response to the vaccine.
What is the current status of trial NCT01924754?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2014-01-01. Estimated completion is 2016-05-31.
What conditions does trial NCT01924754 study?
This clinical trial studies the following conditions: HPV Seroconversion.
Who is sponsoring clinical trial NCT01924754?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01924754 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.